Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04204473
Recruitment Status : Recruiting
First Posted : December 19, 2019
Last Update Posted : June 11, 2020
Sponsor:
Information provided by (Responsible Party):
TYK Medicines, Inc

Brief Summary:
The primary objective of this study is to evaluate the safety and tolerability of TY-9591, with dose-escalation stage and dose-expansion stage.

Condition or disease Intervention/treatment Phase
NSCLC Drug: TY-9591(10mg,40mg) qd. po Phase 1

Detailed Description:
  • To define the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D)
  • To investigate the pharmacokinetic profile of TY-9591 and its metabolites after single then multiple doses of TY-9591 administered orally once daily
  • To evaluate the anti-cancer activity of TY-9591 in NSCLC patients with EGFR mutation(ORR、PFS、DoR、DCR、and CBR)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, Open-label, Single-arm Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of TY-9591 Tablets in Advanced NSCLC Patients With Epidermal Growth Factor Receptor( EGFR) Positive Mutation
Actual Study Start Date : May 7, 2020
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TY-9591
Find maximum tolerated dose of TY-9591 given orally. Escalating doses of TY-9591 starting at 20mg daily.
Drug: TY-9591(10mg,40mg) qd. po
Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
Other Name: TY-9591




Primary Outcome Measures :
  1. Dose Limiting Toxicity (DLT) [ Time Frame: First 29 days of dosing ]
    Incidence of Dose Limiting Toxicity (DLT)

  2. Maximum Tolerated Dose (MTD) [ Time Frame: 1year ]
    To determine the Maximum Tolerated Dose (MTD) of TY-9591 in subjects with NSCLC

  3. Recommended Phase 2 dose (RP2D) [ Time Frame: through study completion, an average of 2.5 years ]
    Recommended Phase 2 dose (RP2D) of TY-9591 in subjects with NSCLC

  4. Overall Response Rate (ORR) [ Time Frame: At least 24 weeks ]
    ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)


Secondary Outcome Measures :
  1. Cmax [ Time Frame: pharmacokinetics(PK) blood samples are collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12, 24, 48, 72,96,120,144,168 and 192 hours post-dose. ]
    Cmax of TY-9591 following single dose

  2. Tmax [ Time Frame: pharmacokinetics(PK) blood samples are collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12, 24, 48, 72,96,120,144,168 and 192 hours post-dose. ]
    Tmax of TY-9591 following single dose

  3. Area Under Curve(AUC) [ Time Frame: pharmacokinetics(PK) blood samples are collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12, 24, 48, 72,96,120,144,168 and 192 hours post-dose ]
    AUC of TY-9591 following single dose

  4. Cmax [ Time Frame: The datas should be evaluated multiple times on Cycle 1 day1,8,15, 21 pre-dose; Cycle 2 day1 (at pre-dose, 0.5,1, 2, 3, 4, 6, 8, 10,12, 24 hours post-dose). Each cycle is 21 days ]
    Cmax of TY-9591 following multiple dose

  5. Cmin [ Time Frame: The datas should be evaluated multiple times on Cycle 1 day1,8,15, 21 pre-dose; Cycle 2 day1 (at pre-dose, 0.5,1, 2, 3, 4, 6, 8, 10,12, 24 hours post-dose). Each cycle is 21 days ]
    Cmin of TY-9591 following multiple dose

  6. AUC [ Time Frame: The datas should be evaluated multiple times on Cycle 1 day1,8,15, 21 pre-dose; Cycle 2 day1 (at pre-dose, 0.5,1, 2, 3, 4, 6, 8, 10,12, 24 hours post-dose). Each cycle is 21 days ]
    AUC of TY-9591 following multiple dose

  7. Progression-free survival (PFS) [ Time Frame: 10.1 months ]
    PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by by Investigator assessment in accordance to RECIST 1.1

  8. Duration of Response (DOR) [ Time Frame: 9.7 months ]
    DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by Investigator assessment in accordance to RECIST 1.1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18-75years old, male or female.
  2. Histological or cytological confirmation diagnosis of NSCLC
  3. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
  4. Life expectancy of at least 3 months.
  5. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
  6. Documentation of disease progression while on previous continuous treatment with first-line EGFR TKI; patients must have confirmation of tumor EGFR activating mutations (exon 19 del, or exon 21 ) and T790M mutation status
  7. Adequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    a.Neutrophils (absolute value) ≥ 1.5×10^9/L; b.Hemoglobin ≥ 90 g/L; c.Platelet ≥ 80×10^9/L; d.Serum total bilirubin ≤ 1.5× ULN(for Patients with Gilbert Syndrome, total bilirubin ≤ 3×ULN and bilirubin ≤ 1.5×ULN should be permitted) f. Aspartate aminotransferase(AST)、alanine aminotransferase(ALT) ≤ 2.5×ULN; for patients with hepatic metastases, AST、ALT ≤ 5×ULN; g. International standardized ratio (INR) < 1.5, and activated partial prothrombin time (APTT) < 1.5×ULN;

  8. Female subjects have a negative urine or serum pregnancy.
  9. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.

Exclusion Criteria:

  1. Treatment with any of the following:

    1. Treatment with an EGFR TKI within 14 days or about 5x half-life, whichever is the longer, of the first dose of study drug;
    2. Any cytotoxic chemotherapy, investigational agents or anticancer drugs for the treatment from a previous treatment regimen within 4 weeks of the first dose of study treatment;
    3. Major surgery within 4 weeks of the first dose of study treatment;
    4. Radiotherapy with a limited field of radiation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 4 weeks of the first dose of study treatment;
    5. Previously treated by other third-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) for T790M (for example Osimertinib).
    6. Patients currently receiving (or at least within 1 week prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4.
  2. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy.
  3. Spinal cord compression or brain metastases unless asymptomatic.
  4. Dysphagia, or active digestive system diseases or previous significant bowel resection or medical conditions potentially affect TY-9591 absorption.
  5. Cardiac function and disease are consistent with the following:

    1. Corrected QT interval(QTc)> 470 milliseconds from 3 electrocardiograms (ECGs);
    2. Any clinically important abnormalities in rhythm;
    3. Any factors that increase the risk of QTc prolongation;
    4. Left ventricular ejection fraction (LVEF) <50%;
  6. Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers.

7 .Previous history of interstitial lung disease(ILD)、drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases.

8. Previous allogeneic bone marrow transplant. 9. Hypersensitivity to TY-9591 or similar compounds or excipients. 10.Pregnant or lactating women.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04204473


Contacts
Layout table for location contacts
Contact: Baohui Han, MD 18930858216 18930858216@163.com

Locations
Layout table for location information
China
Shanghai Chest Hospital Recruiting
Shanghai, China, 201203
Contact: Baohui Han, MD    18930858216    18930858216@163.com   
Sponsors and Collaborators
TYK Medicines, Inc
Investigators
Layout table for investigator information
Principal Investigator: Baohui Han, MD Shanghai Chest Hospital
Layout table for additonal information
Responsible Party: TYK Medicines, Inc
ClinicalTrials.gov Identifier: NCT04204473    
Other Study ID Numbers: TYKM1601101
First Posted: December 19, 2019    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases